Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Loser - TheStreet

Arena Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 2%. By the end of trading, Arena Pharmaceuticals fell 25 cents (-2.4%) to $9.98 on average volume. Throughout the day, 21.8 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 21.7 million shares. The stock ranged in price between $9.86-$10.57 after having opened the day at $10.45 as compared to the previous trading day's close of $10.23. Other company's within the Drugs industry that declined today were:

Anthera Pharmaceuticals



), down 16.1%,

Aoxing Pharmaceutical Company



), down 11.5%,




), down 11.1%, and

Supernus Pharmaceuticals



), down 9.1%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.25 billion and is part of the

health care

sector. Shares are up 447.1% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a


. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the positive front,

Prima Biomed Ltd. ADR



), up 43.4%,

Ampio Pharmaceuticals



), up 28.9%,

K-V Pharmaceutical Company



), up 21.7%, and

K-V Pharmaceutical Company



), up 14.9%, were all gainers within the drugs industry with

Johnson & Johnson



) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech